Qualify: A randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia

Schizophrenia Research

Volumn 168, Issue 1-2, 2015, Pages 498-504

  Naber, Dieter ^a   Hansen, Karina ^b   Forray, Carlos ^c   Baker, Ross A ^d   Sapin, Christophe ^b   Beillat, Maud ^b   Peters Strickland, Timothy ^d   Nylander, Anna Greta ^e   Hertel, Peter ^e   Andersen, Henrik Steen ^e   Eramo, Anna ^c   Loze, Jean Yves ^f   Potkin, Steven G ^g  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Lundbeck   (France)

^c LUNDBECK RESEARCH USA   (United States)

^d OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^e H LUNDBECK A S   (Denmark)

^f Otsuka Pharmaceutical Europe Ltd   (United Kingdom)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antipsychotic treatment; Aripiprazole; Clinical trial; Functioning; Long acting injectable; QLS

Indexed keywords

ARIPIPRAZOLE; PALIPERIDONE; NEUROLEPTIC AGENT;

ADULT; AKATHISIA; ARTICLE; BODY WEIGHT DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; EXTRAPYRAMIDAL SYNDROME; FEMALE; FOLLOW UP; HEINRICHS CARPENTER QUALITY OF LIFE SCALE; HUMAN; INJECTION SITE PAIN; INSOMNIA; INVESTIGATOR ASSESSMENT QUESTIONNAIRE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE RIGIDITY; MUSCLE SPASM; NAUSEA; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREMOR; WEIGHT GAIN; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; PSYCHOLOGICAL RATING SCALE; REGRESSION ANALYSIS; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEAST-SQUARES ANALYSIS; MALE; PALIPERIDONE PALMITATE; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SCHIZOPHRENIA; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 84942367326     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.07.007     Document Type: Article

References (26)

1. Boyer L., Millier A., Perthame E., Aballea S., Auquier P., Toumi M. Quality of life is predictive of relapse in schizophrenia. BMC Psychiatry 2013, 13:15.
2. Emsley R., Chiliza B., Asmal L. The evidence for illness progression after relapse in schizophrenia. Schizophr. Res. 2013, 148:117-121.
3. Falissard B., Sapin C., Loze J.Y., Landsberg W., Hansen K. Defining the minimal clinically important difference of the Heinrichs-Carpenter Quality of Life Scale (QLS). Int. J. Methods Psychiatr. Res. 2015, (in press).
4. Fleischhacker W.W., Gopal S., Lane R., Gassmann-Mayer C., Lim P., Hough D., Remmerie B., Eerdekens M. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int. J. Neuropsychopharmacol. 2012, 15:107-118.
5. Fleischhacker W.W., Sanchez R., Johnson B., Jin N., Forbes R.A., McQuade R., Baker R.A., Carson W., Kane J.M. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. Int. Clin. Psychopharmacol. 2013, 28:171-176.
6. Fleischhacker W.W., Sanchez R., Perry P.P., Jin N., Peters-Strickland T., Johnson B.R., Baker R.A., Eramo A., McQuade R.D., Carson W.H., Walling D., Kane J.M. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br. J. Psychiatry 2014, 205:135-144.
7. Guy W. ECDEU Assessment Manual for Psychopharmacology 1976, Government Printing Office, Washington, DC.
8. Hasan A., Falkai P., Wobrock T., Lieberman J., Glenthoj B., Gattaz W.F., Thibaut F., Moller H.J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J. Biol. Psychiatry 2013, 14:2-44.
9. Heinrichs D.W., Hanlon T.E., Carpenter W.T. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr. Bull. 1984, 10:388-398.
10. Hough D., Gopal S., Vijapurkar U., Lim P., Morozova M., Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr. Res. 2010, 116:107-117.
11. Jones P.B., Barnes T.R., Davies L., Dunn G., Lloyd H., Hayhurst K.P., Murray R.M., Markwick A., Lewis S.W. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch. Gen. Psychiatry 2006, 63:1079-1087.
12. Kane J.M., Sanchez R., Perry P.P., Jin N., Johnson B.R., Forbes R.A., McQuade R.D., Carson W.H., Fleischhacker W.W. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 2012, 73:617-624.
13. Kishimoto T., Nitta M., Borenstein M., Kane J.M., Correll C.U. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J. Clin. Psychiatry 2013, 74:957-965.
14. Lewis S.W., Barnes T.R., Davies L., Murray R.M., Dunn G., Hayhurst K.P., Markwick A., Lloyd H., Jones P.B. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr. Bull. 2006, 32:715-723.
15. Li H., Rui Q., Ning X., Xu H., Gu N. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:1002-1008.
16. Lieberman J.A. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 2004, 18:251-267.
17. Lieberman J.A., Jarskog L.F., Malaspina D. Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection. J. Clin. Psychiatry 2006, 67:983-990.
18. Nasrallah H.A., Gopal S., Gassmann-Mayer C., Quiroz J.A., Lim P., Eerdekens M., Yuen E., Hough D. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology 2010, 35:2072-2082.
19. Pandina G., Lane R., Gopal S., Gassmann-Mayer C., Hough D., Remmerie B., Simpson G. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:218-226.
20. Perkins D.O. Predictors of noncompliance in patients with schizophrenia. J. Clin. Psychiatry 2002, 63:1121-1128.
21. Stahl S.M. Long-acting injectable antipsychotics: shall the last be first?. CNS Spectr. 2014, 19:3-5.
22. Tandon R., Devellis R.F., Han J., Li H., Frangou S., Dursun S., Beuzen J.N., Carson W., Corey-Lisle P.K., Falissard B., Jody D.N., Kujawa M.J., L'italien G., Marcus R.N., McQuade R.D., Ray S., Van P.P. Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder. Psychiatry Res. 2005, 136:211-221.
23. Taylor D., Hanssens L., Loze J.Y., Pans M., L'italien G., Marcus R.N. Preference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole vs standard of care: results from the STAR study. Eur. Psychiatry 2008, 23:336-343.
24. Thwin S.S., Hermes E., Lew R., Barnett P., Liang M., Valley D., Rosenheck R. Assessment of the minimum clinically important difference in quality of life in schizophrenia measured by the Quality of Well-Being Scale and disease-specific measures. Psychiatry Res. 2013, 209:291-296.
25. Tiihonen J., Haukka J., Taylor M., Haddad P.M., Patel M.X., Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am. J. Psychiatry 2011, 168:603-609.
26. Wiens B.L. Choosing an equivalence limit for noninferiority or equivalence studies. Control. Clin. Trials 2002, 23:2-14.